Previous close | 0.7000 |
Open | N/A |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 3.50 |
Expiry date | 2024-12-20 |
Day's range | 0.7000 - 0.7000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
FOSTER CITY, Calif., June 07, 2024--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.